An important aspect of the CiPA (Comprehensive In Vitro Proarrhythmia Assay) proposal is the use of human stem cell-derived cardiomyocytes and the confirmation of their predictivity in drug safety assays.… Click to show full abstract
An important aspect of the CiPA (Comprehensive In Vitro Proarrhythmia Assay) proposal is the use of human stem cell-derived cardiomyocytes and the confirmation of their predictivity in drug safety assays. The benefits of this cell source are clear, drugs can be tested in vitro on human cardiomyocytes, with patient-specific genotypes if needed, and differentiation efficiencies are generally excellent, resulting in a virtually limitless supply of cardiomyocytes.
               
Click one of the above tabs to view related content.